{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.250","value":"14.78"},{"groupId":"OG001","spread":"31.088","value":"8.33"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"25"}],"units":"Participants"}],"description":"Global health status/quality of life is a subscale of the EORTC QOL C30, which comprises two questions related to overall health/quality of life during the past week. The raw score to each question ranged from 1 (very poor) to 7 (excellent). The raw mean score of health status/quality of life subscale is calculated for each participant and a linear transformation applied to standardize the raw score, so that scores range from 0 to 100; a higher score represents a higher (\"better\") health and quality of life.","dispersionType":"Standard Deviation","groups":[{"description":"Velcade 1.3 mg/m2 was administered as an intravenous bolus injection according to the current approved package inserts. Melphalan 9 mg/m2 and prednisone 60 mg/m2 were taken orally.","id":"OG000","title":"Part 2: VMP (Velcade+Melphalan+Prednisone)"},{"description":"Siltuximab 11 mg/kg as a 1-hour intravenous infusion every 3 weeks along with VMP. VMP: Velcade 1.3 mg/m2 was administered as an intravenous bolus injection according to the current approved package inserts. Melphalan 9 mg/m2 and prednisone 60 mg/m2 were taken orally.","id":"OG001","title":"Part 2: VMP (Velcade+Melphalan+Prednisone) + Siltuximab"}],"paramType":"MEAN","populationDescription":"Intent-to-treat (ITT) population: all randomized participants with evaluable data during baseline and Cycle 9","reportingStatus":"POSTED","timeFrame":"Baseline (Day 1 predose) and Cycle 9 (Week 54)","title":"Change From Baseline to Cycle 9 in Global Health Status/Quality of Life Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ C30)","type":"SECONDARY","unitOfMeasure":"Scores on a scale"}